NEUREN PHARMACEUTICALS LIMITED

1.73%

$16.48

Market Cap $2.076B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

Latest Threads

Tag

Subject

NEU

Acadia

24 25 26

16:59

1.5K

784K

16:59

Last post kens

1.5K

784K

NEU

Neuren Media and Analyst Coverage

29 30 31

09:42

1.8K

1.0M

09:42

Last post imback

1.8K

1.0M

NEU

Share Price

269 270 271

25/07/25

16K

8.0M

25/07/25

Last post Vapor

16K

8.0M

NEU

NEU chart

38 39 40

25/07/25

2.3K

1.3M

25/07/25

Last post turbo

2.3K

1.3M

NEU

Ann: Change of Director's Interest Notice - J Pilcher

24/07/25

11K

24/07/25

Last post TomDi

11K

NEU

Dividend reinvestment plan for Neu

23/07/25

12K

23/07/25

Last post Snozz

12K

NEU

Katelin’s Turn is HERE!!!

4 5 6

23/07/25

329

211K

23/07/25

Last post mellan

329

211K

NEU

Ann: Application for quotation of securities - NEU

22/07/25

860

22/07/25

Last post 10%jump

860

See All Discussions

Timeline

Change of Director's Interest Notice - J Pilcher
22 Jul 09:30	Share

Application for quotation of securities - NEU
22 Jul 09:21	Share

Notification regarding unquoted securities - NEU
09 Jul 17:03	Share

Application for quotation of securities - NEU
30 Jun 17:49	Share

US patent allowed for NNZ-2591 to treat Pitt Hopkins
26 Jun 09:25	Share

Notification of cessation of securities - NEU
25 Jun 17:26	Share

Update - Notification of buy-back - NEU
16 Jun 09:28	Share

Update - Notification of buy-back - NEU
16 Jun 09:07	Share

Update - Notification of buy-back - NEU
13 Jun 08:26	Share

Update - Notification of buy-back - NEU
12 Jun 07:45	Share

Update - Notification of buy-back - NEU
11 Jun 08:07	Share

Update - Notification of buy-back - NEU
10 Jun 08:33	Share

Update - Notification of buy-back - NEU
06 Jun 09:13	Share

Update - Notification of buy-back - NEU
05 Jun 07:50	Share

Notification of cessation of securities - NEU
04 Jun 16:30	Share

Update - Notification of buy-back - NEU
04 Jun 08:30	Share

Update - Notification of buy-back - NEU
03 Jun 08:38	Share

Update - Notification of buy-back - NEU
02 Jun 08:51	Share

Update - Notification of buy-back - NEU
30 May 08:41	Share

Update - Notification of buy-back - NEU
29 May 08:00	Share

Update - Notification of buy-back - NEU
28 May 07:31	Share

Results of Meeting
27 May 12:17	Share

AGM Chair Address & CEO Presentation
27 May 10:19	Share

Update - Notification of buy-back - NEU
27 May 08:41	Share

Update - Notification of buy-back - NEU
26 May 09:11	Share

Notification regarding unquoted securities - NEU
23 May 17:15	Share

Approval of long-term equity incentive
23 May 11:51	Share

Update - Notification of buy-back - NEU
23 May 08:43	Share

Update - Notification of buy-back - NEU
22 May 08:21	Share

Update - Notification of buy-back - NEU
21 May 07:31	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $16.48		Change -0.290(1.73%)		Mkt cap ! $2.076B

Open	High	Low	Value	Volume
$16.58	$16.74	$16.40	$9.107M	549.9K

Buyers (Bids)

No.	Vol.	Price($)
1	864	$16.43

Sellers (Offers)

Price($)	Vol.	No.
$16.50	1668	1

View Market Depth

No.	Vol.	Price($)
1	864	16.430
1	2500	16.400
1	306	16.300
1	35	16.150
1	50	16.050

Price($)	Vol.	No.
16.620	58	1
16.720	100	1
16.750	300	1
16.890	1266	1
16.950	75	1

Last trade - 16.10pm 25/07/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Neuren Pharmaceuticals (ASX:NEU) partner drug approved as first treatment for Rett syndrome

13 Mar 2023 10:53 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) receives FDA approval for Prader-Willi syndrome phase II trial

23 Jan 2023 11:16 (AEDT)

Latest Articles

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Neuren Pharma (ASX:NEU) has seen its shares jump over +11% as the company wins a patent to treat Pitt Hopkins Syndrome...

FDA OK for Neuren's first ever Phase 3 trial in children with Phelan-McDermid syndrome

Neuren has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome.

Neuren set for FDA talks on trial to treat developmental genetic disorders

Neuren Pharmaceuticals is set to enter talks with the Us Food and Drug Administration about its upcoming trial.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News